New research has confirmed the link between bisphoshonates, such as Fosamax, and atypical femur fractures, a type of thigh fracture that occurs spontaneously, without any major leg injury. The study, published in the Archives of Internal Medicine, also found that the risk of atypical thigh fractures increases the longer a patient … [Read more...] about Bisphosphonate Study Confirms Atypical Thigh Fracture Risk

A new U.S. Food & Drug Administration (FDA) analysis is raising serious concerns about the long-term use of bisphosphonates like Fosamax to treat weak bones. While the bisphosphonate analysis found little if any benefit from taking the drugs for more than three to five years, the FDA has stopped short of issuing any sort of … [Read more...] about FDA Bisphosphonate Study Finds Few Benefits from Long-Term Use

Federal drug regulators in the U.S. are currently reviewing two conflicting studies examining a possible association between oral bisphosphonates, like Fosamax, and esophageal cancer. According to a report in The Wall Street Journal, it’s difficult to discern which of the studies reached correct conclusions regarding oral … [Read more...] about Conflicting Studies on Oral Bisphosphonates, Esophageal Cancer Yield Confusion